The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

New threats posed by the emerging circulating variants of SARS-CoV-2 highlight the need to
find conserved neutralizing epitopes for therapeutic antibodies and efficient vaccine design …

Potent neutralizing antibodies (nAbs) against SARS-CoV-2 are a promising therapeutic
against the ongoing COVID-19 pandemic. However, the continuous emergence of …

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering
most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an …

SARS-CoV-2 continues to evolve and evade most existing neutralizing antibodies, including
all clinically authorized antibodies. We have isolated and characterized two human …

The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the
effectiveness of antibody therapeutics necessitates development of next-generation …

Continued evolution of the SARS-CoV-2 spike poses a challenge to immune interventions.
To develop antibodies that protect against evolving SARS-CoV-2 viruses, we combined …

Despite effective countermeasures, SARS-CoV-2 persists worldwide due to its ability to
diversify and evade human immunity 1. This evasion stems from amino-acid substitutions …

Abstract COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused
over 5 million deaths to date. Although multiple vaccines are available, breakthrough …